logo
logo

IgGenix Completes $10 Million Series A Financing

Aug 04, 2020•almost 5 years ago

Amount Raised

$10 Million

Round Type

series a

San Francisco

Description

IgGenix, Inc, today announced it completed a $10 million Series A financing. The financing was led by Khosla Ventures with participation from Parker Ventures and will be used to advance the company’s novel antibody therapeutics platform for the treatment of food and non-food allergies and other severe allergic conditions.

Company Information

Company

Ig Genix

Location

San Francisco, California, United States

About

IgGenix is a privately held biotechnology company taking a revolutionary approach to directly address food and other severe allergies by reengineering key antibodies involved in the allergic cascade. Founded based on research by professors Stephen Quake, Kari Nadeau, and Derek Croote of Stanford University, IgGenix isolates allergen-specific IgE antibodies and transforms them into IgG antibodies that alleviate and possibly prevent the allergic cascade. This novel approach may prevent life-threatening allergic reactions, saving lives and reducing the constant fear that affects people living with severe allergies. For more information, visit www.IgGenix.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech